How Do Donor-recipient CMV Serostatus and Post-hematopoietic Stem Cell Transplantation CMV Reactivation Affect Outcomes in Acute Leukemia Patients?

This study evaluated CMV serostatus in donors and recipients of hematopoietic stem cell transplantation (HSCT) and its effects on CMV reactivation of patients and all aspects of CMV on HSCT outcomes.
Subjects and Seven hundred and five adult acute leukemia patients (AML=408 and AML=297) who had undergone HSCT were included in this retrospective study. We categorized donor-recipient pairs in three risk groups: positive donors (D) were studied as high-risk group, including either R or R-(n=485), R-D- as low-risk group (n=32) and R as intermediate group (n=15).
There was no statistically difference in CMV reactivation among these risk groups (P=0.14).CMV infection rate was lower in R than R(p=0.050). Multivariate analysis showed that patients developing CMV infection had lower overall survival (p=0.04, HR: 1.43, CI=1.00- 2.05) and higher non- relapse mortality (P=0.01, HR: 1.62, CI=1.11-2.38). Relapse rate did not change in CMV reactivated patients (P=0.94).
The results of the study indicated that asCMV reactivation occurred more in R patients compared to R ones, and was associated with inferior OS and higher NRM it could be suggested that in contrast to general belief, if the recipient is seropositive ,seropositive donor is preferred to a seronegative one.